A new Supreme Court ruling just cracked the door for civil RICO lawsuits in legal cannabis. If you think this won’t hit your dispensary, think again. Here’s what every grower, brand, and budtender needs to know.
Can Congress Fix Weed, or Just Finish Off the Movement?
Congressman Dave Joyce wants credit for fixing weed. But his new legislation might just carve up the movement and hand it to corporate stakeholders. Behind the clean language is a blueprint for state-by-state chaos, not freedom. If this is legalization, it’s legalization without justice—and the people who built the culture are still waiting outside the gates.
DEA Stalls on Cannabis Rescheduling: What’s the Hold-Up?
The DEA is dragging its feet on cannabis rescheduling despite over 43,000 public comments and a formal Schedule III recommendation from HHS. What’s the hold-up? This deep-dive exposes the legal limbo, political stall tactics, and why America’s weed policy is still frozen in time.
Joint Custody: Why Parents Are Still Hiding Their Weed Use
It’s 2025 and parents are still hiding their weed like it’s a crime—even in states where it’s legal. From PTA paranoia to custody fears, the stigma is alive and well. We unpack the double standards, the culture clash with alcohol, and why honesty about weed and parenting is still radical. This is the high-functioning rebellion no one talks about.
Pot Culture Magazine’s April 2025 Cover: A Culture at a Crossroads
Cannabis culture is at a turning point. This month's cover reflects the tension—progress on one side, resistance on the other. As legalization faces a new wave of scrutiny and misinformation, the future isn’t guaranteed. It’s being shaped now, by the people paying attention.
The DEA’s Stance on Rescheduling: Progress or Stalemate?
The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.